Financial News Feed

Previous Hold Today AKTX ranks #2334 as HOLD CANDIDATE #2334 Next Hold

Akari Therapeutics Plc stock forecast

AKTX stock forecast

Akari Therapeutics EPS beats by $0.05
12:06pm, Wednesday, 29'th May 2019
No summary available....

Read more

In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants administered intravitreally, reported: ○ Significant improvement in clinical scoring versus control ○ Co-localization of LTB4 and C5a receptors in retinal inflammatory cells seen for the first time ○ Significant downregulation of pro-inflammatory T-helper 17 cells and the inflammatory cytokine IL-17 ○ Efficacy of LTB4 and C5 inhibition, supporting its potential as a novel, non-steroidal therapy across a range of severe ‘back-of-eye' diseases In a "first in eye" Phase I/II study in atopic keratoconjunctivitis (AKC) initial surface of the eye data from the first two patients, treated topically, nomacopan (Coversin) demonstrated: ○ No serious drug related adverse events and good tolerability ○ Rapid improvement in mean comfort and composite efficacy endpoint scores compared to baseline on cyclosporin ○ In allergic conjunctivitis, an eye surface disease, elevated levels of LTB4 were observed NEW YORK and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye. "This positive initial data from our ophthalmology program supports the potential efficacy of LTB4 and C5 inhibition in eye surface and back-of-the-eye diseases....

Read more

NEW YORK , April 24, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ACB: Full story available on Benzinga.com...

Read more

Akari Therapeutics reports Q4 results
08:13pm, Tuesday, 23'rd Apr 2019
Akari Therapeutics (AKTX): Q4 GAAP EPS of $0.00. Cash of $5.4M Press Release...

Read more

Gainers: Atossa Genetics (ATOS) +28%. Immunic (IMUX) +22%. Akari Therapeutics (AKTX) +19%. Superconductor Technologies (SCON) +18%. X4 Pharmaceuticals (XFO...

Read more

Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for autoimmune and inflammatory diseases — announced positive Phase 2 results for nomacopan, or Coversin, which is being evaluated for bullous pemphigoid, a severe inflammatory skin disease. Akari is also evaluating Coversin for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy. The midstage trial studied up to nine mild-to-moderate bullous pemphigoid patients in a six-week, open-label, single-arm study that evaluated safety and efficacy. They results measured using the bullous pemphigoid … Full story available on Benzinga.com...

Read more

No summary available....

Read more

This is a contrast between Rubius Therapeutics Inc. (NASDAQ:RUBY) and Akari Therapeutics Plc (NASDAQ:AKTX) based on their dividends, analyst recommendations, institutional ownership, profitability, ri...

Read more

As we move closer towards the end of the year, investors might be looking over the portfolio and trying to see what has been working and what hasn’t been. Investors may be studying the most recent e...

Read more

Akari Therapeutics (AKTX) touched 3.58 on a recent bid indicating that the Tenkan line is still hovering below the Kijun Sen. This represents bearish momentum for the shares. Whether or not the shares...

Read more

Both Soligenix Inc. (NASDAQ:SNGX) and Akari Therapeutics Plc (NASDAQ:AKTX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends,...

Read more

Akari Therapeutics Plc (NASDAQ:AKTX) and PDL BioPharma Inc. (NASDAQ:PDLI) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, analyst recomm...

Read more

We are comparing Akari Therapeutics Plc (NASDAQ:AKTX) and ImmuCell Corporation (NASDAQ:ICCC) on their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and val...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank